Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
telmisartan + bisoprolol
- Development stage
- Unknown
- Lead developer
- Medical University of Vienna
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
telmisartan + bisoprolol is a combination therapy consisting of an angiotensin II receptor blocker (ARB) and a selective beta-1 adrenergic receptor blocker. This specific combination was evaluated by the Medical University of Vienna in the PONTIAC (NT-proBNP Guided Prevention of Cardiovascular Events in Diabetic Patients) clinical trial. The therapeutic strategy involves using these two agents to provide intensified cardiac prevention care in patients with diabetes mellitus who exhibit elevated NT-proBNP levels but have no prior history of cardiac disease. Telmisartan functions by selectively blocking the binding of angiotensin II to the AT1 receptor, leading to vasodilation and reduced aldosterone secretion. Bisoprolol is a cardioselective beta-blocker that reduces heart rate and myocardial contractility by inhibiting beta-1 adrenergic receptors. The goal of the combination in this context is to reduce cardiac workload and prevent the progression to overt cardiovascular events.
- Brand names
- TELMOTO-B25TELMOTO-B-25TELMOTO-B 25TELMOTO-B 2.5TELMOTO-B2.5TELMOTO-B-2.5
- Other names
- Telmisartan and Bisoprolol
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)ADRB1 (β1)
Beyond the preview
Go deeper on telmisartan + bisoprolol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on telmisartan + bisoprolol.